China: Food, Drugs, Healthcare, Life Sciences

Subscribe

Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.

China's New Regulatory Data Protection Regime Becomes Effective Immediately

China's National Medical Products Administration has introduced a groundbreaking regulatory data protection framework that grants up to six years of clinical data exclusivity for pharmaceuticals.

China Healthcare

JD

Jones Day

Breaking: China Released Drug Trial Data Protection Implementation Measures

China's National Medical Products Administration has finalized groundbreaking regulatory data protection measures that grant up to 6 years of market exclusivity for innovative drugs, fundamentally...

China Healthcare

EI

Eagle IP

Protected: China | Data Exclusivity Comes Into Effect

China's National Medical Products Administration has introduced new Implementation Measures for the Protection of Drug Trial Data, establishing a dual-track system of patent and data protection for pharmaceuticals. The measures grant data exclusivity periods ranging from 3 to 6 years for innovative drugs, improved new drugs, and generic drugs, with significant changes from earlier drafts including removal of time-gap reductions and extended protection for improved formulations.

China Healthcare

SF

Spruson & Ferguson

China Compliance Update: Life Sciences — Spring 2026

In 2026, Chinese regulators have continued their focus on anti-corruption enforcement in the life sciences industry.

China Healthcare

AP

Arnold & Porter

China Boosts Medical Innovation For Public Health

China Healthcare

AC

AFD China

China’s Pharma Innovators Pursue A Range Of Deal Structures To Support Global Expansion

China Healthcare

AO

A&O Shearman

China Compliance Update: Life Sciences — Spring 2026

China Healthcare

AP

Arnold & Porter

China | Market Exclusivity And Data Exclusivity Included In Drug Administration Law Revisions

China Healthcare

SF

Spruson & Ferguson

USITC Will Investigate State Support And Pricing Practices By Chinese Biotechnology Firms

China Healthcare

BC

Bergeson & Campbell

China Life Sciences: 2025 Year In Review

China Healthcare

AP

Arnold & Porter

China On The Move: Key Takeaways From The 2025 NRDL Negotiations And Adjustment

China Healthcare

GT

Greenberg Traurig, LLP

A Legal Commentary On The Latest Implementing Regulations Of The PRC Drug Administration Law

China Healthcare

FP

Fangda Partners

Navigating China's Health Transformation: Opportunities And Challenges For Multinationals

China Healthcare

AC

Ankura Consulting Group LLC

Ten Minefields: A Guide To Avoiding Pitfalls In Applying For Human Genetic Resources Projects In China

China Healthcare

HK

Han Kun Law Offices

红筹架构迎严监管：企业赴港上市前拆除红筹的实践路径探析

China Commercial

JT

Beijing Jincheng Tongda & Neal Law Firm

Application Of The Research Exemption And Infringement Determination In Pesticide Patent Disputes

AC

AFD China

China's Anti-Unfair Competition Law Enters Full Implementation: Five Regulatory Signals And What They Mean For IP Protection

China Anti-trust

CT

Chang Tsi & Partners

从《智能体新规》看AI智能体的风险防范与合规治理（上）

China Technology

AB

AnJie Broad Law Firm

China’s Pharma Innovators Pursue A Range Of Deal Structures To Support Global Expansion

China Healthcare

AO

A&O Shearman

See more

Food and Drugs Law

China's New Regulatory Data Protection Regime Becomes Effective Immediately

China's National Medical Products Administration has introduced a groundbreaking regulatory data protection framework that grants up to six years of clinical data exclusivity for pharmaceuticals.

China Healthcare

JD

Jones Day

Protected: China | Data Exclusivity Comes Into Effect

China's National Medical Products Administration has introduced new Implementation Measures for the Protection of Drug Trial Data, establishing a dual-track system of patent and data protection for pharmaceuticals. The measures grant data exclusivity periods ranging from 3 to 6 years for innovative drugs, improved new drugs, and generic drugs, with significant changes from earlier drafts including removal of time-gap reductions and extended protection for improved formulations.

China Healthcare

SF

Spruson & Ferguson

Breaking: China Released Drug Trial Data Protection Implementation Measures

China's National Medical Products Administration has finalized groundbreaking regulatory data protection measures that grant up to 6 years of market exclusivity for innovative drugs, fundamentally...

China Healthcare

EI

Eagle IP

国家知识产权局发布2025年度专利复审无效典型案例

AC

AFD China

2025年度专利复审无效典型案例

AC

AFD China

China Compliance Update: Life Sciences — Spring 2026

China Healthcare

AP

Arnold & Porter

SRS v. Alexion药品许可诉讼案评析——兼论中国创新药企BD合同的风险防控与条款设计

China Commercial

JT

Beijing Jincheng Tongda & Neal Law Firm

China Boosts Medical Innovation For Public Health

China Healthcare

AC

AFD China

China’s Pharma Innovators Pursue A Range Of Deal Structures To Support Global Expansion

China Healthcare

AO

A&O Shearman

See more

Life Sciences, Biotechnology & Nanotechnology

China's New Regulatory Data Protection Regime Becomes Effective Immediately

China's National Medical Products Administration has introduced a groundbreaking regulatory data protection framework that grants up to six years of clinical data exclusivity for pharmaceuticals.

China Healthcare

JD

Jones Day

Breaking: China Released Drug Trial Data Protection Implementation Measures

China's National Medical Products Administration has finalized groundbreaking regulatory data protection measures that grant up to 6 years of market exclusivity for innovative drugs, fundamentally...

China Healthcare

EI

Eagle IP

国家知识产权局发布2025年度专利复审无效典型案例

近日，国家知识产权局遴选出十件关注度高、影响力大、具备指导价值的2025年度专利复审无效典型案例，以深入阐释专利审查标准，明晰专利保护规则...

AC

AFD China

China Releases 2025 Typical Cases On Patent Reexamination And Invalidation

AC

AFD China

China Compliance Update: Life Sciences — Spring 2026

China Healthcare

AP

Arnold & Porter

SRS v. Alexion药品许可诉讼案评析——兼论中国创新药企BD合同的风险防控与条款设计

China Commercial

JT

Beijing Jincheng Tongda & Neal Law Firm

Judicial Assessment Of Usage Limitations' Impact On The Novelty Of Product Claims

AC

AFD China

外資の研究開発投資が拡大　中国、世界のイノベーション拠点

China Government

K

Kangxin

A Stratification Too Far? How The CNIPA Draws The Line On Patient Subgroups In A Recent Precision Medicine Invalidation Case

EI

Eagle IP

See more

Healthcare

China's New Regulatory Data Protection Regime Becomes Effective Immediately

China's National Medical Products Administration has introduced a groundbreaking regulatory data protection framework that grants up to six years of clinical data exclusivity for pharmaceuticals.

China Healthcare

JD

Jones Day

Protected: China | Data Exclusivity Comes Into Effect

China's National Medical Products Administration has introduced new Implementation Measures for the Protection of Drug Trial Data, establishing a dual-track system of patent and data protection for pharmaceuticals. The measures grant data exclusivity periods ranging from 3 to 6 years for innovative drugs, improved new drugs, and generic drugs, with significant changes from earlier drafts including removal of time-gap reductions and extended protection for improved formulations.

China Healthcare

SF

Spruson & Ferguson

China Releases 2025 Typical Cases On Patent Reexamination And Invalidation

China's national intellectual property administration (CNIPA) has released ten typical cases from 2025 involving patent reexamination and invalidation. These cases were selected because they are highly relevant...

AC

AFD China

China Boosts Medical Innovation For Public Health

China Healthcare

AC

AFD China

Beijing Intellectual Property Court Releases 2025 Annual Case List

AC

AFD China

China Compliance Update: Life Sciences — Spring 2026

China Healthcare

AP

Arnold & Porter

China On The Move: Key Takeaways From The 2025 NRDL Negotiations And Adjustment

China Healthcare

GT

Greenberg Traurig, LLP

2025年度广告合规洞察：监管新规下的合规之道

China Media & IT

FP

Fangda Partners

开启直播电商合规新纪元 |《直播电商监督管理办法》重点解读（下）

China Media & IT

FP

Fangda Partners

See more

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More